An interventional study of Active Sonodyn and Sham in Myofascial Pain Syndrome - Lower Back, Myofascial Pain Syndrome - Neck and Myofascial Pain Syndrome - Tension Headache, sponsored by Sobet AG. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Sobet AG · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Sonodyn is an investigational device that within this clinical investigation is intended for use in patients suffering from low back pain, tension headache or neck pain, originating from therapy-resistant myofascial pain syndrome.
Myofascial pain syndrome is a prevalent pain condition in the adult population and a common cause of pain and dysfunction in the musculoskeletal system. It is a trigger point-induced regional musculoskeletal pain disorder affecting one or more muscles or groups of muscles.
Sonodyn is a handheld medical device that combines low-energy ultrasound, electrical and magnetic field stimulation for non-invasive transcutaneous treatment of chronic myofascial pain syndrome. Sonodyn is a battery-operated, rechargeable stimulation device to be placed over specific trigger points for associated pain patterns in the human body. It emits ultrasound, electrical and magnetic stimulation signals with a pre-defined set of parameters for each of the independently operated power sources.
The study will follow a prospective, randomized, sham-controlled, double-blind parallel group design. It will be conducted as a multi-center investigation at 6 sites in Austria and Switzerland. Patients are randomized in a 2:1 ratio into Treatment and Control.
Two types of Sonodyn devices will be used: a fully functional one for Therapy arm patients that can deliver stimulation, and a non-functional one for Control arm patients that cannot convey any energy signals to the device output. The devices will look fully identical.
Randomization will be stratified by study site, pain diagnosis and sex of the patient.
For each subject, after a screening phase of 1 week, patients will be treated for 3 weeks with a follow-up of additional 8 weeks, adding up to 12 weeks. During treatment patients will activate their device 3 times a day for 10 minutes each.
During screening, treatment and follow-up period, all patients will twice per day report the average and maximum intensity of their pain Numeric Rating Scale (NRS). Patients will also enter the date, amount, and time of intake of rescue medication, if applicable.
The primary objective of this study is to assess the impact on pain. Secondary objectives are to compare the performance between active therapy and sham, as well as to correlate changes in pain intensity with other pain related scales.
340 studies on the registry are indexed under Myofascial Pain Syndromes; 67 are open to participants now.
This study's planned enrollment of 126 is above the median of 51 across 308 interventional studies indexed under Myofascial Pain Syndromes.
Browse Myofascial Pain Syndromes studies →This is the only study on the registry with Sobet AG as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient is suffering from one of the following chronic pain conditions originating from myofascial pain:
having been persisting for a minimum of 3 months and where myofascial pain syndrome is the pre-dominant cause for pain.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will remain on treatment for 3 weeks and will activate their device 3 times a day for 10 minutes each.
Device: Active Sonodyn
Patients will remain on sham treatment for 3 weeks and will activate their device 3 times a day for 10 minutes each.
Device: Sham
Sonodyn emits ultrasound, electrical and magnetic stimulation signals with a pre-defined, fixed set of parameters for each of the independently operated power sources.
Non-functional Sonodyn device that cannot convey any energy signals to the device output, however, looks and behaves fully identical as the active Sonodyn device.
Average Numeric Rating Scale (NRS)
Change in Treatment group from Baseline to EoT in average Numeric Rating Scale (NRS, 0-10, with 0 indicating no pain and 10 indicating the worst pain that the patient had ever experienced) per day
Time frame: 3 weeks
Difference in average NRS between groups - Baseline to EoT
Difference between groups in change of average NRS from Baseline to EoT
Time frame: 3 weeks
Maximum NRS - Baseline to EoT
Change from Baseline to EoT in maximum NRS in both groups
Time frame: 3 weeks
Average and maximum NRS - Baseline to end of follow-up
Change from Baseline to end of follow-up in average and maximum NRS in both groups
Time frame: 11 weeks
AUC of average and maximum NRS - Baseline to EoT
Baseline-adjusted area under the curve (AUC) of average and maximum NRS from Baseline to EoT in both groups
Time frame: 3 weeks
Average and maximum NRS - Follow-up
Average and maximum NRS during follow-up in both groups
Time frame: 8 weeks
Medication consumption
Pain and rescue medication consumption during treatment and follow-up phase in both groups
Time frame: 11 weeks
EQ-5D-5L
EQ-5D-5L questionnaire from Baseline to EoT and end of follow-up
Time frame: 11 weeks
Quality of sleep
Quality of sleep questionnaire from Baseline to EoT and end of follow-up
Time frame: 11 weeks
Socioeconomic data
Change in socioeconomic data from Screening to EoT
Time frame: 4 weeks
Safety Outcome #1
Adverse Events (AEs), Adverse Device Effects (ADEs), and Device Deficiencies (DDs) observed until EoT
Time frame: 3 weeks
Safety Outcome #2
Serious Adverse Events (SAEs), Serious Adverse Device Effects (SADEs), and related AEs observed until end of follow-up
Time frame: 11 weeks
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Mar 2027, 46 months after the start.
Of 205 interventional studies with no phase under Myofascial Pain Syndromes, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's planned 46 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.